In line with intrahepatic MCP-1, circulating MCP-1 was supported by some authors to be elevated in patients with NASH versus those with hepatic steatosis or controls [141, 142], as well as in patients with significant fibrosis versus those with mild or no fibrosis [143]. Here, CCL2 is linked to metabolic dysfunction-associated steatohepatitis.